MedTrace Logo

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

NCT00966602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-01-05

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics and safety of co-administration of VX-770 and VX-809 in healthy adults.

Conditions

Interventions

DRUG

VX-809

VX-809 capsule, once daily for 14 days

DRUG

VX-770

VX-770 tablet, once every 12 hours for 14 days

DRUG

VX-809 & VX-770

VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966602 on ClinicalTrials.gov